Sarah Kuhl

Dr. Sarah Kuhl

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
Elizabeth KutterElizabeth Kutter
Elizabeth Kutter
DVDaniel De Vos
Daniel De Vos
GGGuram Gvasalia
Guram Gvasalia
ZAZemphira Alavidze
Zemphira Alavidze
LGLasha Gogokhia
Lasha Gogokhia
SAStephen T. Abedon
Stephen T. Abedon
Phage therapy is the application of bacteria-specific viruses with the goal of reducing or eliminating pathogenic or nuisance bacteria. While phage therapy has become a broadly relevant technology, including veterinary, agricultural, and food microbiology applications, it is for the treatment or prevention of human infections that phage therapy first caught the worlds imagination - see, especially, Arrowsmith by Sinclair Lewis (1925) - and which today is the primary motivator of the field. Nonetheless, though the first human phage therapy took place in the 1920s, by the 1940s the field, was in steep decline despite early promise. The causes were at least three-fold: insufficient understanding among researchers of basic phage biology; over exuberance, which led, along with ignorance, to carelessness; and the advent of antibiotics, an easier to handle as well as highly powerful category of antibacterials. The decline in phage therapy was neither uniform nor complete, especially in the former Soviet Republic of Georgia, where phage therapy traditions and practice continue to this day. In this review we strive toward three goals: 1. To provide an overview of the potential of phage therapy as a means of treating or preventing human diseases; 2. To explore the phage therapy state of the art as currently practiced by physicians in various pockets of phage therapy activity around the world, including in terms of potential

1 July 2016 in Journal of Wound Care
Verified
Journal Article
Closed access
RFR. Fish
R. Fish
EKE. Kutter
E. Kutter
GWG. Wheat
G. Wheat
BBB. Blasdel
B. Blasdel
MKM. Kutateladze
M. Kutateladze
SKSarah Kuhl
Sarah Kuhl
Diabetic foot ulcer (DFU) infections are a growing public health problem, with increasing prevalence, poor response to antibiotics and bacterial resistance to traditional antimicrobials leading to increased morbidity and mortality. Bacteriophages (phages), the viruses that target specific bacteria, are one option for addressing bacterial infections, especially where antibiotics fail. Of particular value is a class of virulent staphylococcal phages that hit almost all Staphylococcus aureus, including most methicillin-resistant Staphylococcus aureus (MRSA) strains. Here we report a continuous case series assessing the effectiveness of treating infected and poorly vascularised toe ulcers with exposed bone, after failure of recommended antibiotic therapy, using topically applied Staphylococcus aureus-specific phage. This was a compassionate-use case series of nine patients with diabetes and poorly perfused toe ulcers containing culture-proven Staphylococcus aureus infected bone and soft tissue, who had responded poorly to recommended antibiotic therapy. Six representative cases are presented here. The only generally accepted other option in each case was toe amputation. Exposed portions of the infected phalanges were removed in three cases and left in place in two cases. One case presented as a micro-clot induced gangrene following vascular stenting. In this case, phage were used to prevent infection. The phage used was a commercially available fully sequenced preparation of staphylococcal phage Sb-1. Phage solution was applied topically to the ulcerations once weekly, following standard good wound care. The amount of phage solution applied varied from 0.1 to 0.5 cc depending on volume and area of the ulceration. All infections responded to the phage applications and the ulcers healed in an average of seven weeks with infected bone debridement. One ulcer, where vascularity was extremely poor and bone was not removed to preserve hallux function, required 18 weeks of treatment. In the case of the toe with the micro-clot gangrene, the toe was salvaged and healed in seven weeks without complications. Topical application of a staph mono-phage preparation can be used successfully to treat infected toe ulcerations with bone involvement, despite very poor vascularity and failure of antibiotic treatment. The success within this small series provides the groundwork for controlled clinical trials of staph phage for diabetic foot infections.

22 May 2015 in Future Microbiology
Verified
Journal Article
Closed access
EKElizabeth Martin Kutter
Elizabeth Martin Kutter
SKSarah Kuhl
Sarah Kuhl
SAStephen T Abedon
Stephen T Abedon

2 October 2018 in Antibiotics
Verified
Journal Article
Open access
PDF file
RFRandolph Fish
Randolph Fish
Elizabeth KutterElizabeth Kutter
Elizabeth Kutter
DBDaniel Bryan
Daniel Bryan
GWGordon Wheat
Gordon Wheat
SKSarah Kuhl
Sarah Kuhl
Infections involving diabetic foot ulcers (DFU) are a major public health problem and have a substantial negative impact on patient outcomes. Osteomyelitis in an ulcerated foot substantially increases the difficulty of successful treatment. While literature suggests that osteomyelitis in selected patients can sometimes be treated conservatively, with no, or minimal removal of bone, we do not yet have clear treatment guidelines and the standard treatment failure fallback remains amputation. The authors report on the successful treatment, with a long term follow up, of a 63 YO diabetic female with distal phalangeal osteomyelitis using bacteriophage, a form of treatment offering the potential for improved outcomes in this era of escalating antibiotic resistance and the increasingly recognized harms associated with antibiotic therapy.

1 June 1993 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
SKSarah Kuhl
Sarah Kuhl
YTYajarayma J. Tang
Yajarayma J. Tang
LNLorena Navarro
Lorena Navarro
PGPaul H. Gumerlock
Paul H. Gumerlock
JSJoseph Silva
Joseph Silva
Toxigenic Clostridium difficile is the etiologic agent of pseudomembranous colitis. We have developed an assay system for the rapid direct detection of toxigenic C. difficile in human stool samples. After DNA extraction, polymerase chain reaction (PCR) amplification is undertaken with primers targeting specific sequences in the C. difficile 16S rRNA gene. Next, toxigenic strains of C. difficile are distinguished from nontoxigenic strains by PCR amplification of toxin A and/or B gene sequences. This study included 12 patients with C. difficile colitis, seven of whom had clinical relapses after discontinuation of vancomycin therapy. We detected toxigenic C. difficile in stools from four (57%) of these seven patients before relapse—at a time when no toxin B was detectable in stools and results of anaerobic culture were negative. The PCR assay is 100-fold more sensitive than anaerobic culture methods. The course of the infection in one patient (both during and after therapy) was monitored by the PCR technique. The multigene analysis approach permitted the detection of colonization with a nontoxigenic strain when this patient's relapses had cleared. This clinically applicable assay allows earlier detection of infection with toxigenic C. difficile. The result is more timely therapeutic intervention.

22 June 2015 in Journal of Applied Behavior Analysis
Verified
Journal Article
Closed access
PDF file
SKSarah Kuhl
Sarah Kuhl
EREric H. Rudrud
Eric H. Rudrud
BWBenjamin N. Witts
Benjamin N. Witts
KSKimberly A. Schulze
Kimberly A. Schulze